Literature DB >> 27496654

Activation of delta-opioid receptor contributes to the antinociceptive effect of oxycodone in mice.

Pao-Pao Yang1, Geng-Chang Yeh2, Teng-Kuang Yeh3, Jinghua Xi4, Horace H Loh4, Ping-Yee Law4, Pao-Luh Tao5.   

Abstract

Oxycodone has been used clinically for over 90 years. While it is known that it exhibits low affinity for the multiple opioid receptors, whether its pharmacological activities are due to oxycodone activation of the opioid receptor type or due to its active metabolite (oxymorphone) that exhibits high affinity for the mu-opioid receptors remains unresolved. Ross and Smith (1997) reported the antinociceptive effects of oxycodone (171nmol, i.c.v.) are induced by putative kappa-opioid receptors in SD rat while others have reported oxycodone activities are due to activation of mu- and/or delta-opioid receptors. In this study, using male mu-opioid receptor knock-out (MOR-KO) mice, we examined whether delta-opioid receptor was involved in oxycodone antinociception. Systemic subcutaneous (s.c.) administration of oxycodone (above 40mg/kg) could induce a small but significant antinociceptive effect in MOR-KO mice by the tail flick test. Delta-opioid receptor antagonist (naltrindole, 10mg/kg or 20mg/kg, i.p.) could block this effect. When oxycodone was injected directly into the brain of MOR-KO mice by intracerebroventricular (i.c.v.) route, oxycodone at doses of 50nmol or higher could induce similar level of antinociceptive responses to those observed in wild type mice at the same doses by i.c.v. Delta-opioid receptor antagonists (naltrindole at 10nmol or ICI 154,129 at 20μg) completely blocked the supraspinal antinociceptive effect of oxycodone in MOR-KO mice. Such oxycodone antinociceptive responses were probably not due to its active metabolites oxymorphone because (a) the relative low level of oxymorphone was found in the brain after systemically or centrally oxycodone injection using LC/MS/MS analysis; (b) oxymorphone at a dose that mimics the level detected in the mice brain did not show any significant antinocieption effect; (c) oxycodone exhibits equal potency as oxymorphone albeit being a partial agonist in regulating [Ca(2+)]I transients in a clonal cell line expressing high level of mu-opioid receptor. These data suggest that oxycodone by itself can activate both the mu- and delta-opioid receptors and that delta-opioid receptors may contribute to the central antinociceptive effect of oxycodone in mice.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antinociceptive; DAMGO (PubChem CID: 5462471); Etorphine (PubChem CID: 443407); Morphine (PubChem CID: 528826); Naloxone hydrochloride (PubChem CID: 5464092); Naltrindole hydrochloride (PubChem CID: 24840086); Opioid receptors; Oxycodone; Oxycodone hydrochloride (PubChem CID: 5462350); Oxymorphone; Oxymorphone (PubChem CID: 5284604)

Mesh:

Substances:

Year:  2016        PMID: 27496654     DOI: 10.1016/j.phrs.2016.05.034

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  7 in total

1.  Oxycodone-induced tolerance to respiratory depression: reversal by ethanol, pregabalin and protein kinase C inhibition.

Authors:  Rob Hill; William L Dewey; Eamonn Kelly; Graeme Henderson
Journal:  Br J Pharmacol       Date:  2018-05-07       Impact factor: 8.739

2.  Oxycodone decreases anxiety-like behavior in the elevated plus-maze test in male and female rats.

Authors:  Adriaan W Bruijnzeel; Azin Behnood-Rod; Wendi Malphurs; Ranjithkumar Chellian; Robert M Caudle; Marcelo Febo; Barry Setlow; John K Neubert
Journal:  Behav Pharmacol       Date:  2022-08-03       Impact factor: 2.277

3.  Peripherally restricted transthyretin-based delivery system for probes and therapeutics avoiding opioid-related side effects.

Authors:  Md Tariqul Haque Tuhin; Dengpan Liang; Fang Liu; Hala Aldawod; Toufiq Ul Amin; Joshua S Ho; Rasha Emara; Arjun D Patel; Melanie A Felmlee; Miki S Park; James A Uchizono; Mamoun M Alhamadsheh
Journal:  Nat Commun       Date:  2022-06-23       Impact factor: 17.694

4.  A limited access oral oxycodone paradigm produces physical dependence and mesocorticolimbic region-dependent increases in DeltaFosB expression without preference.

Authors:  Vishakh Iyer; Taylor J Woodward; Romario Pacheco; Andrea G Hohmann
Journal:  Neuropharmacology       Date:  2021-12-15       Impact factor: 5.273

5.  Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids.

Authors:  Keith M Olson; David I Duron; Daniel Womer; Ryan Fell; John M Streicher
Journal:  PLoS One       Date:  2019-06-06       Impact factor: 3.240

Review 6.  Oxycodone in the Opioid Epidemic: High 'Liking', 'Wanting', and Abuse Liability.

Authors:  Cherkaouia Kibaly; Jacob A Alderete; Steven H Liu; Hazem S Nasef; Ping-Yee Law; Christopher J Evans; Catherine M Cahill
Journal:  Cell Mol Neurobiol       Date:  2020-11-27       Impact factor: 4.231

7.  μ-Opioid Receptors on Distinct Neuronal Populations Mediate Different Aspects of Opioid Reward-Related Behaviors.

Authors:  Amie L Severino; Nitish Mittal; Joshua K Hakimian; Nathanial Velarde; Ani Minasyan; Ralph Albert; Carlos Torres; Nicole Romaneschi; Camille Johnston; Suchi Tiwari; Alex S Lee; Anna M Taylor; Claire Gavériaux-Ruff; Brigitte L Kieffer; Christopher J Evans; Catherine M Cahill; Wendy M Walwyn
Journal:  eNeuro       Date:  2020-09-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.